Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 8/20 | 0.63 |
| ▸ | LMNA | P02545 | 8/20 | 0.63 |
| ▸ | MAPT | P10636 | 6/20 | 0.63 |
| ▸ | TSHR | P16473 | 5/20 | 0.63 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.63 |
| ▸ | SHBG | P04278 | 5/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.63 |
| ▸ | SERPINA6 | P08185 | 4/20 | 0.63 |
| ▸ | PGR | P06401 | 4/20 | 0.63 |
| ▸ | AR | P10275 | 4/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.63 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.63 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3672474 | 1.00 | CYP3A4 (0.63) | CYP3A4LMNAMAPTTSHRNR3C1 | |
| SCHEMBL15011284 | 1.00 | CYP3A4 (0.63) | CYP3A4LMNAMAPTTSHRNR3C1 | |
| SCHEMBL3671789 | 0.84 | LMNA (0.69) | CYP3A4LMNAMAPTTSHRNR3C1 | |
| SCHEMBL18438757 | 0.83 | CYP3A4 (0.79) | CYP3A4LMNAMAPTTSHRNR3C1 | |
| SCHEMBL7996078 | 0.83 | CYP3A4 (0.79) | CYP3A4LMNAMAPTTSHRNR3C1 | |
| SCHEMBL2082800 | 0.83 | CYP3A4 (0.79) | CYP3A4LMNAMAPTTSHRNR3C1 | |
| SCHEMBL4617560 | 0.83 | CYP3A4 (0.79) | CYP3A4LMNAMAPTTSHRNR3C1 | |
| SCHEMBL2600420 | 0.83 | CYP3A4 (0.79) | CYP3A4LMNAMAPTTSHRNR3C1 | |
| SCHEMBL4617563 | 0.83 | CYP3A4 (0.79) | CYP3A4LMNAMAPTTSHRNR3C1 | |
| SCHEMBL15369348 | 0.83 | CYP3A4 (0.79) | CYP3A4LMNAMAPTTSHRNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170360673-A1 | HAIR COMPOSITION | CONOPCO, INC., D/B/A UNILEVER (US) | 2017-12-21 | — | — | US | claimed |
| US-20140295010-A1 | SKIN ANTI-AGEING COMPOSITION | CONOPCO, INC. D/B/A UNILEVER (US) | 2014-10-02 | — | — | US | claimed |
| EP-1627030-A1 | NITROGEN REJECTION FROM CONDENSED NATURAL GAS | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2006-02-22 | — | — | EP | claimed |
| WO-2004104143-A1 | NITROGEN REJECTION FROM CONDENSED NATURAL GAS | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2004-12-02 | — | — | WO | claimed |
| WO-2004103376-A2 | SKIN TREATMENTS | UNILEVER PLC (GB) | 2004-12-02 | — | — | WO | claimed |
| EP-1432399-A1 | ENHANCING EPIDERMAL BARRIER DEVELOPMENT IN SKIN | UNILEVER PLC (GB) | 2004-06-30 | — | — | EP | claimed |
| US-20030124159-A1 | Enhancing epidermal barrier development in skin | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC | 2003-07-03 | — | — | US | claimed |
| WO-2003030857-A1 | ENHANCING EPIDERMAL BARRIER DEVELOPMENT IN SKIN | UNILEVER PLC (GB) | 2003-04-17 | — | — | WO | claimed |
| CN-107106628-B | Hair composition | 荷兰联合利华有限公司 | 2021-01-12 | — | — | CN | disclosed |
| US-10456344-B2 | Hair composition | CONOPCO, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-10406091-B2 | Skin anti-ageing composition | CONOPCO, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| EP-2788088-B1 | SKIN ANTI-AGEING COMPOSITION | UNILEVER PLC (GB) | 2019-06-19 | — | — | EP | disclosed |
| US-20170360673-A1 | HAIR COMPOSITION | CONOPCO, INC., D/B/A UNILEVER (US) | 2017-12-21 | — | — | US | disclosed |
| EP-2788088-A1 | SKIN ANTI-AGEING COMPOSITION | Unilever Plc. (GB) | 2014-10-15 | — | — | EP | disclosed |
| WO-2004104143-A1 | NITROGEN REJECTION FROM CONDENSED NATURAL GAS | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2004-12-02 | — | — | WO | disclosed |
| WO-2004103376-A2 | SKIN TREATMENTS | UNILEVER PLC (GB) | 2004-12-02 | — | — | WO | disclosed |
| WO-2004103320-A2 | SKIN TREATMENTS | UNILEVER PLC (GB) | 2004-12-02 | — | — | WO | disclosed |
| EP-1432399-A1 | ENHANCING EPIDERMAL BARRIER DEVELOPMENT IN SKIN | UNILEVER PLC (GB) | 2004-06-30 | — | — | EP | disclosed |
| US-20030124159-A1 | Enhancing epidermal barrier development in skin | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC | 2003-07-03 | — | — | US | disclosed |
| WO-2003030857-A1 | ENHANCING EPIDERMAL BARRIER DEVELOPMENT IN SKIN | UNILEVER PLC (GB) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030124159-A1 | Enhancing epidermal barrier development in skin | NR1H2, NR1H3, RXRB | CYP3A4 3038/4885LMNA 1129/4885MAPT 3673/4885 |
| US-10456344-B2 | Hair composition | GLS2, GLS, LHCGR | CYP3A4 2039/4885LMNA 1277/4885MAPT 3943/4885 |
| US-20170360673-A1 | HAIR COMPOSITION | GLS2, GLS, CYP17A1 | CYP3A4 2268/4885LMNA 1391/4885MAPT 4235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.